09:30 AM EDT, 07/18/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Thursday its phase 3 trial assessing Ajovy's effectiveness in preventing episodic migraine in children and adolescents reached its primary endpoint.

The drug candidate reached a "statistically significant superior efficacy" during 12 weeks of treatment compared with placebo, the company said.

The safety data was similar to that seen in adults, Teva said, adding there were no emergent safety signals.

Complete data from the trial will be presented at a medical event later this year, the company said.

Price: 16.50, Change: +0.12, Percent Change: +0.73